University Staff

hong kong university logo queen mary hosipital logo

Dr. Thomas H.Y. LEUNG (梁浩然博士)

Post-doctoral Fellow
BSc (HKUST); MPhil (CUHK); PhD (HKU)
  • location
    L7-47, Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong
  • telephone
    (852)-3917-9368
  • facsimile
    (852)-2816-1947
  • thyl@hku.hk
Research Interests
  • Cell signaling pathways in gynaecological cancers
  • Identification and characterization of tumor suppressor genes/oncogenes in gynaecological cancers.

Publications

2014
  • Chan KKL, Leung THY, Chan DW, Wei N, Lau TY, Liu S, Siu KY and Ngan HYS. Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer. Journal of Endocrinology 2014, 221: 325-336.

  • Cai C, Shi L, Liu VWS, Tang WM, Liu J, Leung THY, Chan KKL, Yam JWP, Yao KM, Ngan HYS and Chan DW. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget 2014, 5: 7549-62.

2013
  • Kwan HT, Chan DW, Cai PC, Mak CS, Yung MM, Leung TH, Wong OG, Cheung AN, Ngan HY. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PLoS One. 2013;8(1):e53597. [PubMed]

  • Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY.The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer. 2013 Aug 20;109(4):965-75. [PubMed]

2012
  • Chan DW, Hui WY, Cai C, Liu X, Yung MH, Mak SL, Leung THY, Chan KKL, Ngan HYS. Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells. PLoS ONE. 2012, 7: e52578. [PubMed]

  • Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget. 2012 Dec;3(12):1546-56. [PubMed]

  • Fung FK, Chan DW, Liu VW, Leung TH, Cheung AN, Ngan HY. Increased expression of PITX2 transcription factor contributes to ovarian cancer progression. PLoS One. 2012;7(5):e37076. [PubMed]

2011
  • Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One. 2011;6(8):e23790. [PubMed]

2010
  • Leung TH, Ngan HY. Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiation-induced apoptosis. Cancer Res 2010;70:6486-96. [PubMed]

  • Leung THY, Yam JWP, Chan LK, Ching YP, Ng IOL. DLC2 (Deleted in liver cancer 2) suppresses cell growth via regulation of Raf-1-ERK1/2-p70S6K signaling pathway. Liver International. 2010;30(9):1315-23. (Publication No. : 172119) 

Research Grants
  • General Research Fund (GRF) 2013-2014
    Amount awarded: $ 1,255,747 )
    Roles of HPV-E6 protein and CD55(+) population in regulating radio-resistance in cervical cancer cells.
  • General Research Fund (GRF) 2013-2014 )
    Amount awarded: $ 736,128
    Differential roles of estrogen receptor subtypes and variants in ovarian cancer: implications for personalized hormonal treatment.
  • Small Project Funding (HKU) 2012 (Principle Investigator)
    Amount awarded: $69,575 )
    Clinical correlation of DNp73, C35 and HER2 and their cooperative effects in ovarian cancer.
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $50,500
    Roles of CD55(+) population and HPV viral proteins on tumor progression in cervical cancer cells
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $61,100
    Characterization of tumor initiating cell population expressing CD55 in cervical cancer.
  • General Research Fund (GRF) 2011-2012 (Co-Investigator)
    Amount awarded: $ 950,000
    Functional characterization and clinical significance of DNp73-C35 in ovarian cancer
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $58,000
    Title: Functional role of DNp73-C35 interaction in chemo-resistance of ovarian cancer.
  • Small Project Funding (HKU) (Principle Investigator)
    Amount awarded: $45,574
    Title: Identification and characterization of cancer stem cells in cervical cancer
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $67,000
    Title: Selective hormonal treatment in ovarian cancer
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $70,000
    Title: Functional characterization and clinical significance of C35-DNp73 in ovarian cancer
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $110,000
    Title: The role of PDCD4 gene in ovarian carcinogenesis
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $100,000
    Title: Regulation of TP73 functions by BCA3 and clinical significance of BCA3 gene in cervical cancer
  • Small Project Funding (HKU) (Principle Investigator)
    Amount awarded: $54,502
    Title: Characterization of BCA3, a novel binding partner of p73 in cervical cancer
  • Seed Funding Programme for Basic Research (HKU) (Co-Investigator)
    Amount awarded: $106,000
    Title: Differential expression of DeltaNp73 controlling the radiotherapeutic response in cervical cancers
  • Small Project Funding (HKU) (Principle Investigator)
    Amount awarded: $80,000
    Title: Functional characterization of DLC2 in suppression of cancer cell growth and tumorigenicity in liver cancer
Awards and Honors
  • AACR Scholar-in-Training Award. Special Conference: Cell death mechanisms and cancer therapy, 2010 (San Diego, USA)
  • Young Investigator Award 2004. 4th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences, 2004
  • AACR Scholar-in-Training Award. 95th American Association for Cancer Research Annual Meeting (Florida, USA), 2004